Serum S100B Levels Correlate with Clinical Benefit in a Metastatic Melanoma Patient Treated by CTLA-4 Blockade: A Case Report

Publisher： Karger

E-ISSN： 2296-5262|36|10|578-581

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.36, Iss.10, 2013-09, pp. : 578-581

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Febrile Neutropenia in a Metastatic Melanoma Patient Treated with Ipilimumab - Case Report

By  

Oncology Research and Treatment, Vol. 38, Iss. 3, 2015-02 ,pp. : 105-108

Karger

Access to resources Recommend Favorite

Clinical significance of serum S100B levels in neurointensive care

By  

Neurocritical Care, Vol. 6, Iss. 2, 2007-04 ,pp. : 94-99

Humana Press, Inc

Access to resources Recommend Favorite

Long-Term Survival Analysis in Metastatic Melanoma: Serum S100B Is an Independent Prognostic Marker and Superior to LDH

By  

Oncology Research and Treatment, Vol. 31, Iss. 7, 2008-06 ,pp. : 380-384

Karger

Access to resources Recommend Favorite

S100B Protein Detection in Serum Is a Significant Prognostic Factor in Metastatic Melanoma

By  

Oncology, Vol. 56, Iss. 4, 1999-05 ,pp. : 338-344

Karger

Access to resources Recommend Favorite

Serum Protein S-100 Predicts Clinical Outcome in Patients with Melanoma Treated with Adjuvant Interferon – Comparison with Tyrosinase RT-PCR

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 341-349

Karger

Access to resources Recommend Favorite